Isotretinoin in Treating Young Patients With High-Risk Neuroblastoma

• Status: Unknown status
• Trial end date: 1969-12-31
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors plan better treatment for patients receiving isotretinoin.

PURPOSE: This clinical trial is studying the side effects and best dose of isotretinoin in treating young patients with high-risk neuroblastoma.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Children's Cancer and Leukaemia Group
• Treatments: Isotretinoin

Criteria

DISEASE CHARACTERISTICS:

• Histologically confirmed high-risk neuroblastoma

• Concurrent isotretinoin as part of clinical treatment

PATIENT CHARACTERISTICS:

• Not pregnant

• Fertile patients must use effective contraception

• Has a single- or double-lumen central venous catheter in place

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics